Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China · Delayed Price · Currency is CNY 9.84
-0.29 (-2.86%)
Aug 24, 2026, 3:05 PM CST
Yifan Pharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 751.21 | 732.97 | 889.39 | 698.37 | 1,144 | 1,336 |
Trading Asset Securities | - | - | - | 75.01 | 95.5 | - |
Cash & Short-Term Investments | 751.21 | 732.97 | 889.39 | 773.38 | 1,239 | 1,336 |
Cash Growth | -14.08% | -17.59% | 15.00% | -37.59% | -7.25% | -2.51% |
Accounts Receivable | 1,580 | 1,571 | 1,507 | 1,209 | 1,258 | 1,145 |
Other Receivables | 84.75 | 92.49 | 105.57 | 80.69 | 112.08 | 120.16 |
Receivables | 1,665 | 1,664 | 1,612 | 1,290 | 1,370 | 1,265 |
Inventory | 1,172 | 1,258 | 1,056 | 928.61 | 830.97 | 663.87 |
Other Current Assets | 279.08 | 267.47 | 220.86 | 259.62 | 249.71 | 320.22 |
Total Current Assets | 3,867 | 3,922 | 3,778 | 3,251 | 3,690 | 3,585 |
Property, Plant & Equipment | 2,750 | 2,701 | 2,144 | 1,752 | 1,601 | 1,643 |
Long-Term Investments | 664.23 | 693.04 | 691.26 | 717.04 | 696.68 | 640.12 |
Goodwill | 2,737 | 2,737 | 2,737 | 2,737 | 2,738 | 2,738 |
Other Intangible Assets | 1,645 | 1,668 | 1,826 | 1,683 | 751.37 | 658.21 |
Long-Term Accounts Receivable | - | - | - | - | 2.16 | - |
Long-Term Deferred Tax Assets | 256.53 | 258.22 | 245.21 | 257.81 | 291.47 | 244.38 |
Long-Term Deferred Charges | 708.75 | 730.22 | 773.65 | 964.14 | 2,592 | 2,474 |
Other Long-Term Assets | 216.24 | 135.14 | 90.04 | 137.51 | 181.38 | 182.71 |
Total Assets | 12,845 | 12,845 | 12,286 | 11,500 | 12,544 | 12,165 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 794.58 | 873.39 | 609.12 | 431.36 | 288.4 | 350.86 |
Accrued Expenses | 117.43 | 387.04 | 393.79 | 387.69 | 360.56 | 219.84 |
Short-Term Debt | 1,084 | 1,204 | 1,058 | 609.05 | 673.96 | 1,020 |
Current Portion of Long-Term Debt | 298.44 | 248.98 | 544.67 | 489.77 | 554.03 | 419.27 |
Current Portion of Leases | - | 12.07 | 14.22 | 17.6 | 17.95 | 14.54 |
Current Income Taxes Payable | 68.91 | 33.78 | 29.21 | 19.14 | 29.54 | 24.19 |
Current Unearned Revenue | 127.4 | 124.89 | 113.63 | 133.23 | 203.26 | 94.82 |
Other Current Liabilities | 400.95 | 149.19 | 224.76 | 99.53 | 71.69 | 158.53 |
Total Current Liabilities | 2,892 | 3,033 | 2,987 | 2,187 | 2,199 | 2,302 |
Long-Term Debt | 957.82 | 858.9 | 627.16 | 812.04 | 850.17 | 730.51 |
Long-Term Leases | 34.55 | 38.93 | 50.56 | 66.73 | 80.69 | 89.8 |
Long-Term Unearned Revenue | 131.7 | 133.87 | 121.21 | 102.16 | 107.29 | 104.12 |
Long-Term Deferred Tax Liabilities | 41.05 | 42.11 | 46.51 | 54.52 | 140.9 | 148.28 |
Other Long-Term Liabilities | 27.19 | 27.16 | 26.49 | 21.86 | 18.94 | 16.02 |
Total Liabilities | 4,084 | 4,134 | 3,859 | 3,245 | 3,397 | 3,391 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 1,037 | 1,037 | 1,037 | 1,046 | 1,046 | 1,054 |
Additional Paid-In Capital | 2,847 | 2,847 | 2,848 | 2,993 | 2,993 | 3,048 |
Retained Earnings | 5,006 | 4,899 | 4,618 | 4,354 | 4,905 | 4,712 |
Treasury Stock | - | - | - | -159 | -121.01 | -186.72 |
Comprehensive Income & Other | 6.08 | 51.79 | 18.96 | 41.31 | -11.36 | -92.36 |
Total Common Equity | 8,896 | 8,835 | 8,522 | 8,276 | 8,812 | 8,535 |
Minority Interest | -134.69 | -123.55 | -95.07 | -20.73 | 334.75 | 239.38 |
Shareholders' Equity | 8,761 | 8,711 | 8,427 | 8,255 | 9,147 | 8,775 |
Total Liabilities & Equity | 12,845 | 12,845 | 12,286 | 11,500 | 12,544 | 12,165 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 2,375 | 2,363 | 2,294 | 1,995 | 2,177 | 2,274 |
Net Cash (Debt) | -1,624 | -1,630 | -1,405 | -1,222 | -937.51 | -937.76 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -1.33 | -1.34 | -1.16 | -1.00 | -0.74 | -0.77 |
Filing Date Shares Outstanding | 1,217 | 1,037 | 1,216 | 1,216 | 1,219 | 1,207 |
Total Common Shares Outstanding | 1,217 | 1,037 | 1,216 | 1,216 | 1,219 | 1,207 |
Working Capital | 975.2 | 888.84 | 791.21 | 1,064 | 1,491 | 1,284 |
Book Value Per Share | 7.31 | 8.52 | 7.01 | 6.80 | 7.23 | 7.07 |
Tangible Book Value | 4,513 | 4,429 | 3,958 | 3,855 | 5,323 | 5,139 |
Tangible Book Value Per Share | 3.71 | 4.27 | 3.25 | 3.17 | 4.37 | 4.26 |
Buildings | - | 1,382 | 985.62 | 973.8 | 914.2 | 931.78 |
Machinery | - | 1,576 | 1,458 | 1,443 | 1,357 | 1,232 |
Construction In Progress | - | 903.32 | 807.15 | 313.31 | 175.8 | 257.46 |